secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001493152-24-008264
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric signs non-binding term sheets to out-license three compound classes; potential $200M milestones
--------------------------------------------------------------------------------

- Three non-binding term sheets signed with undisclosed biotech for exclusive global out-licenses of three compound classes.
- Potential total milestone payments and execution fees up to $200M if all development and sales criteria are met.
- Royalty rates on each license range from 2.5% to 10% on future sales depending on criteria.
- Compounds from Enveric's Psybrary platform library of over 1,000 novel molecules generated using AI drug discovery.
- Licensee assumes all future preclinical and clinical development costs for human/animal applications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315224008264/0001493152-24-008264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315224008264/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-008264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer